Assessments and analyses
Tumour
TUMOUR
Tumour response was assessed using computed tomography (CT) or magnetic resonance imaging (in the case of CT contraindication). Imaging was performed at baseline and every 6 weeks thereafter, per the investigator using RECIST v1.1 guidelines, including confirmation of complete and PRs at least 28 days after the criteria for response were first met [Plasma samples were collected for all patients for pharmacokinetic (PK) determination of ibrutinib in all cohorts and docetaxel in the GC cohort.